2-氨基-7-甲氧基-4,5-二氢苯并[E]苯并噻吩-1-甲酸甲酯 | 438199-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-氨基-7-甲氧基-4,5-二氢苯并[E]苯并噻吩-1-甲酸甲酯
• 中文别名: 2-氨基-7-甲氧基-4,5-二氢萘并[2,1-B]噻吩-1-甲酸甲酯；2-氨基-7-甲氧基-4,5-二氢萘并[2,1-b]噻吩-1-羧酸甲酯；2-氨基-7-甲氧基-4,5-二氢苯并[E]苯并噻吩-1-羧酸甲酯
• 英文名称: Methyl 2-amino-7-methoxy-4,5-dihydronaphtho[2,1-b]thiophene-1-carboxylate
• 英文别名: methyl 2-amino-7-methoxy-4,5-dihydrobenzo[e][1]benzothiole-1-carboxylate
• CAS: 438199-49-6
• 化学式: C₁₅H₁₅NO₃S
• mdl: MFCD02853943
• 分子量: 289.4
• InChiKey: RITWADYAQOVYSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  89.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090

文献信息

• Heterotricyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080207607A1

  公开（公告）日：2008-08-28

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Heterotricyclic Metalloprotease Inhibitors
  申请人：Gege Christian

  公开号：US20100087420A1

  公开（公告）日：2010-04-08

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• US7749996B2
  申请人：——

  公开号：US7749996B2

  公开（公告）日：2010-07-06
• [EN] HETEROTRICYCLIC METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASE HÉTÉROTRICYCLIQUE
  申请人：ALANTOS PHARM HOLDING

  公开号：WO2008063667A1

  公开（公告）日：2008-05-29

  [EN] The present invention relates generally to azatricyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
  [FR] L'invention concerne, de manière générale, des agents pharmaceutiques contenant de l'azatricyclique, et notamment des composés inhibant la métalloprotéase azatricyclique. Cette invention concerne plus particulièrement une nouvelle classe de composés inhibant les MMP-3, MMP-8 et/ou MMP-13 azatricycliques, qui offre une puissance et une sélectivité améliorées par rapport aux inhibiteurs de MMP-13, MMP-8 et MMP-3 actuellement connus.